Results 131 to 140 of about 5,781 (240)

Parapharyngeal space meningioma

Radiology Case Reports
Parapharyngeal space (PPS) meningiomas are rare extracranial tumors that can mimic more common PPS lesions. We report a case of a 23-year-old female who presented with a painless, progressive neck swelling and intraoral bulge.
Pranjal Rai, MD, Niyati Pokar, MBBS, Animesh Awadhiya, MBBS, Joe Joseph, MD, Dhairya A Lakhani, MD   +4 more
doaj   +1 more source

Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes – [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience – do we need [18F]FDG

, 2020
Anna Zemczak, Maciej Kołodziej, Paweł Gut, Leszek Królicki, Beata Kos‐Kudła, Grzegorz Kamiński, Marek Ruchała, Dariusz Pawlak, Jolanta Kunikowska   +8 more
openalex   +2 more sources

CONTRAST-ENHANCED ULTRASOUND MONITORING OF PERFUSION CHANGES IN HEPATIC NEUROENDOCRINE METASTASES AFTER SYSTEMIC VERSUS SELECTIVE ARTERIAL 177LU/90Y-DOTATOC AND 213BI-DOTATOC RADIOPEPTIDE THERAPY [PDF]

, 2013
Radiopeptide therapy with beta emitter labeled 177Lu/90Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting 213Bi-DOTATOC are promising new treatments for neuroendocrine tumors.
BRUCHERTSEIFER Frank, FLECHSIG Paul, GIESEL Frederik, HABERKORN Uwe, KRATOCHWIL Clemens, KUDER T, SCHWARTZ L, WULFERT Sarah, ZECHMANN Christian   +8 more
core  

Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor

Endocrine Oncology
Metastatic pituitary neuroendocrine tumors (PitNETs) are rare and often aggressive. Patients should be evaluated for metastatic disease when their biochemical presentation is discordant with pituitary tumor burden or when they present with non-pituitary,
Katherine I Wolf, Zhonglin Lu, Elizabeth A Hesseltine, Ka-Kit Wong, Francis P Worden, Tobias Else   +5 more
doaj   +1 more source

First Ex-Vivo Validation of a Radioguided Surgery Technique with beta- Radiation

, 2016
Purpose: A radio-guided surgery technique with beta- -emitting radio-tracers was suggested to overcome the effect of the large penetration of gamma radiation.
Bocci, V., Camillocci, E. Solfaroli, Carollo, A., Chiodi, G., Colandrea, M., Collamati, F., Cremonesi, M., Donnarumma, R., Faccini, R., Ferrari, M. E., Ferroli, P., Ghielmetti, F., Grana, C. M., Marafini, M., Morganti, S., Patanè, M., Pedroli, G., Pollo, B., Recchia, L., Russomando, A., Schiariti, M., Terracciano, C. Mancini, Toppi, M., Traini, G.   +23 more
core   +1 more source

Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy

Frontiers in Oncology
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs
Turgut Bora Cengiz, Raksha Kulkarni, Virginia Corbett, Nasrin V. Ghesani, Edward Wolin, Munir V. Ghesani   +5 more
doaj   +1 more source

Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms

Endocrine Oncology
Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang, Rodney J Hicks, Michael S Hofman, Aravind S Ravi Kumar, Nirupa Sachithanandan, Javad Saghebi, Michael Michael, Grace Kong   +11 more
doaj   +1 more source

Atypical Metastatic Disease in Thyroid from Pancreatic Neuroendocrine Tumor and its Response to [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT): A Promising Therapeutic Option for Somatostatin Receptor Expressing Unusual Metastatic Sites [PDF]

Mali Madhava Reddy, Rahul V. Parghane, Sandip Basu   +2 more
openalex   +1 more source

Orthotopic versus subcutaneous NET: tumor tissue characteristics result in different answers when ADC is used to validate early therapy response following Peptide Receptor Radionuclide Therapy (PRRT) [PDF]

, 2017
Eva J. Koziolek, J. Albrecht, Samantha Exner, Vikas Prasad, Carsten Grötzinger, Winfried Brenner   +5 more
openalex   +1 more source

Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu/²²⁵AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas

Diagnostics
The present report describes the history of a 58-year-old woman with a rapidly progressing neuroendocrine pancreatic tumor (initially G2) presenting with extensive liver, bone, and lymph node metastases.
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge, Andreas Kjaer, Richard P. Baum   +7 more
doaj   +1 more source